158 related articles for article (PubMed ID: 25446855)
1. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
2. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
[TBL] [Abstract][Full Text] [Related]
4. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
5. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
7. Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents.
Kljun J; Anko M; Traven K; Sinreih M; Pavlič R; Peršič Š; Ude Ž; Codina EE; Stojan J; Lanišnik Rižner T; Turel I
Dalton Trans; 2016 Aug; 45(29):11791-800. PubMed ID: 27357845
[TBL] [Abstract][Full Text] [Related]
8. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
9. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
10. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
[TBL] [Abstract][Full Text] [Related]
12. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily.
Jin Y; Duan L; Chen M; Penning TM; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):139-44. PubMed ID: 22210085
[TBL] [Abstract][Full Text] [Related]
14. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis.
Zhao Y; Zheng X; Zhang H; Zhai J; Zhang L; Li C; Zeng K; Chen Y; Li Q; Hu X
Chem Biol Interact; 2015 Oct; 240():310-5. PubMed ID: 26362498
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line.
Kljun J; Pavlič R; Hafner E; Lipec T; Moreno-Da Silva S; Tič P; Turel I; Büdefeld T; Stojan J; Rižner TL
Front Pharmacol; 2022; 13():920379. PubMed ID: 36034868
[TBL] [Abstract][Full Text] [Related]
17. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Palackal NT; Lee SH; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2002 Jul; 277(27):24799-808. PubMed ID: 11978787
[TBL] [Abstract][Full Text] [Related]
18. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
19. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
20. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
